表紙:標的治療薬市場:腫瘍学
市場調査レポート
商品コード
1449703

標的治療薬市場:腫瘍学

Targeted Therapeutics Report : Oncology

出版日: | 発行: Greystone Research Associates | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.10円
標的治療薬市場:腫瘍学
出版日: 2023年11月01日
発行: Greystone Research Associates
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

新規の経路とシグナル伝達を利用した12種類の標的治療が、腫瘍学と抗悪性腫瘍治療の新時代を象徴する結果を達成しました。こうしたアプローチにより、がんの身体的、心理的、感情的負担を軽減する治療法から利益を得ようとする医薬品開発者の数が増加しています。

当レポートでは、標的治療薬市場について調査し、腫瘍学臨床試験の動向と50の治療薬、それらが利用するバイオマーカーについて検証し、セグメント別の動向などをまとめています。

目次

  • エグゼクティブサマリー
  • 組換え薬剤のエコシステム
  • 標的腫瘍治療薬市場のリーダー
  • 腫瘍学生物製剤- 競争力に関する考慮事項
  • 腫瘍標的治療薬として承認された薬剤
  • FDA承認薬
  • EMA承認薬
  • トラスツズマブのバイオシミラー
  • EMA承認済みのバイオシミラー
  • バイオシミラー製品の発売に対する訴訟の影響
  • 標的腫瘍治療薬- 市場セグメント
  • 乳がん
  • 大腸がん
  • 血液がん
  • 肺がん
  • 黒色腫
  • 転移性胃がん
  • 神経系がん
  • 腎細胞がん
  • 尿路上皮がん
  • サプライヤーの競争力評価
目次

Targeted Oncology Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for targeted oncology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Next-generation Therapeutics

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the fifty therapeutic drugs and the biomarkers they utilize.

Here is a Small Sample of the Things You Will Learn:

  • How many suppliers have approved mAb products indicated for one or more types of lung cancer?
  • Who are the API suppliers for the EMA approved version of Adcetris?
  • How many approved biosimilars (FDA and/or EMA) are there for trastuzumab?
  • What is the number of EMA approved biosimilars for oncology indications?
  • Which Daiichi Sankyo facilities in Japan are used for the API and final manufacture of Enhertu?
  • How many approved mAbs are indicated for HER2-positive Breast Cancer?
  • Which two mAbs indicated for oncology are supplied as lyophilized powders for reconstitution?
  • How many approved oncology mAbs target the CD20 antigen?
  • Which supplier is the oncology mAb market leader in terms of revenue?

Table of Contents

  • Executive Summary
  • The Recombinant Drug Ecosystem
  • Targeted Oncology Therapeutics Market Leaders
  • Oncology Biologics - Competitive Considerations
  • Approved Drugs for targeted Oncology Therapeutics
  • FDA-approved Drugs
  • EMA-approved Drugs
  • Biosimilars of Trastuzumab
  • EMA Approved Biosimilars
  • The Impact of Litigation on Biosimilar Product Launches
  • Target Oncology Therapeutics - Market Segments
  • Breast Cancers
  • Colorectal Cancers
  • Hematology Cancers
  • Lung Cancers
  • Melanomas
  • Metastatic Gastric Cancers
  • Neurological Cancers
  • Renal Cell Carcinomas
  • Urothelial Cancers
  • Supplier Competitive Assessments